|
|
News Breaks | | | | November 13, 2012 | | 07:06 EDT |  | ATRS | Antares Pharma announces positive results from MTX Medi-Jey study
Antares Pharma announced positive results from an open-label, randomized, crossover study comparing the systemic availability of MTX Medi-Jet to oral methotrexate in adult patients with rheumatoid arthritis. This study was designed to compare the relative systemic availability of MTX following oral administration to subcutaneous (SC) self-administered MTX using the Medi-Jet device. Patients were assigned to one of four dose levels of MTX, 10 mg, 15 mg, 20 mg, and 25 mg. Results showed that the systemic availability of methotrexate following oral dosing plateaus above 15 mg. Following administration of MTX with Medi-Jet, the systemic availability increased proportionally at every dose, which will extend the range of exposure compared to patients receiving oral therapy. | |
|
News For ATRS From The Last 14 Days Check below for free stories on ATRS the last two weeks. |
|
|
| May 8, 2013 | | 07:03 EDT |  | ATRS | Antares Pharma reports Q1 EPS (3c), consensus (3c)
Reports Q1 revenue $4.53M, consensus $5.12M. Ended the quarter with $80.3M in cash and investments and no debt. | |
|
|
|
|
|
|
